Literature DB >> 7515393

Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.

S H Pincus1, K G Messer, P L Nara, W A Blattner, G Colclough, M Reitz.   

Abstract

Three laboratory workers have been infected with the IIIB strain of HIV; their antibody response to HIV has been studied in serial serum specimens. Because the infecting virus is known, the fine specificity of the antibody response was studied on the homologous strain of HIV. Anti-p17, anti-p24, anti-gp160, CD4/gp120 blocking and neutralizing antibodies developed in parallel. Epitope mapping of the anti-gp160 response indicated several regions that consistently induced an antibody response. Serum contained antibody which reacted with V3-specific peptides corresponding to the very tip of the loop and crossreactivity was seen with V3 loop peptides from other sequence divergent strains of HIV. Antibody to the V1 loop was produced at levels comparable with that seen for the V3-loop. Anti-V1 neutralized HIV with a titration curve equivalent to an anti-V3 monoclonal antibody. Because the infecting virus is known and serial reisolates have been obtained, we explored the relationship between production of antibody to a given epitope and mutation in the virus. The data suggest that an association exists, but do not clearly indicate that antibody drives the selection for mutant viruses. The findings presented here provide a fine specificity analysis of the evolution of the antibody response to HIV in greater detail than has previously been performed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515393      PMCID: PMC294468          DOI: 10.1172/JCI117260

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

2.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

Authors:  L A Lasky; G Nakamura; D H Smith; C Fennie; C Shimasaki; E Patzer; P Berman; T Gregory; D J Capon
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

3.  Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers.

Authors:  S H Weiss; J J Goedert; S Gartner; M Popovic; D Waters; P Markham; F di Marzo Veronese; M H Gail; W E Barkley; J Gibbons
Journal:  Science       Date:  1988-01-01       Impact factor: 47.728

4.  Strategies for epitope analysis using peptide synthesis.

Authors:  H M Geysen; S J Rodda; T J Mason; G Tribbick; P G Schoofs
Journal:  J Immunol Methods       Date:  1987-09-24       Impact factor: 2.303

5.  Quantitative infectivity assay for HIV-1 and-2.

Authors:  P L Nara; P J Fischinger
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

6.  Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.

Authors:  M S Reitz; C Wilson; C Naugle; R C Gallo; M Robert-Guroff
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

7.  Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120.

Authors:  N C Sun; D D Ho; C R Sun; R S Liou; W Gordon; M S Fung; X L Li; R C Ting; T H Lee; N T Chang
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

8.  Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity.

Authors:  B Chesebro; K Wehrly
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

9.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

10.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

View more
  19 in total

1.  Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.

Authors:  Z Wu; S C Kayman; W Honnen; K Revesz; H Chen; S Vijh-Warrier; S A Tilley; J McKeating; C Shotton; A Pinter
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

Review 2.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

Review 3.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

4.  Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1.

Authors:  N V Sipsas; S A Kalams; A Trocha; S He; W A Blattner; B D Walker; R P Johnson
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 5.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

6.  Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.

Authors:  Jie Lan; Kai Yang; Daniel Byrd; Ningjie Hu; Tohti Amet; Nicole Shepherd; Mona Desai; Jimin Gao; Samir Gupta; Yongtao Sun; Qigui Yu
Journal:  J Immunol       Date:  2014-08-22       Impact factor: 5.422

7.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon.

Authors:  M R López-Huertas; S Callejas; D Abia; E Mateos; A Dopazo; J Alcamí; M Coiras
Journal:  Nucleic Acids Res       Date:  2010-02-05       Impact factor: 16.971

9.  Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.

Authors:  Tim Beaumont; Esther Quakkelaar; Ad van Nuenen; Ralph Pantophlet; Hanneke Schuitemaker
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.

Authors:  T Beaumont; A van Nuenen; S Broersen; W A Blattner; V V Lukashov; H Schuitemaker
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.